Table 1 Patient characteristics at baseline
mRNA boost | Vector boost | |
|---|---|---|
n | 24 | 22 |
Age | 63.4 ± 11.4 | 61.2 ± 14.9 |
Sex: female | 10 (41.7) | 7 (31.8) |
Diagnosis (%) | ||
AIH | 1 (4.2) | 0 (0.0) |
CTD | 1 (4.2) | 1 (4.5) |
HTX | 8 (33.3) | 10 (45.5) |
HTX + multiple myeloma | 1 (4.2) | 0 (0.0) |
LiTX | 2 (8.3) | 3 (13.6) |
LiTX + KTX | 1 (4.2) | 0 (0.0) |
LuTX | 5 (20.8) | 6 (27.3) |
Breast cancer | 1 (4.2) | 0 (0.0) |
MS | 2 (8.3) | 0 (0.0) |
Multiple myeloma | 1 (4.2) | 1 (4.5) |
Pemphigus vulgaris | 1 (4.2) | 0 (0.0) |
RCC | 0 (0.0) | 1 (4.5) |
Weeks between 2nd vaccination and screening | 15.2 ± 3.0 | 13.9 ± 4.2 |
Detectable peripheral B-cells (%) | 23 (95.8) | 21 (95.5) |
Tacrolimus (%) | 13 (54.2) | 16 (72.7) |
Mycophenolate (%) | 17 (70.8) | 13 (59.1) |
Everolimus (%) | 2 (8.3) | 2 (9.1) |
Sirolimus (%) | 2 (8.3) | 1 (4.5) |
Ciclosporin (%) | 2 (8.3) | 2 (9.1) |
Daratumumab (%) | 2 (8.3) | 0 (0.0) |
IMiDs (%) | 1 (4.2) | 1 (4.5) |
JAKi (%) | 1 (4.2) | 0 (0.0) |
Hydroxychloroquine (%) | 1 (4.2) | 0 (0.0) |
Fingolimod (%) | 2 (8.3) | 0 (0.0) |
Vinorelbin (%) | 1 (4.2) | 0 (0.0) |
Cabozantinib (%) | 0 (0.0) | 1 (4.5) |
Prednisone (%) | 8 (33.3) | 9 (40.9) |
Number of concomitant immunosuppressants (%) | ||
1 | 6 (25.0) | 5 (22.7) |
2 | 8 (33.3) | 11 (50.0) |
3 | 10 (41.7) | 6 (27.3) |
Primary vaccination (%) | ||
BNT162b2 | 20 (83.3) | 21 (95.5) |
mRNA-1273 | 4 (16.7) | 1 (4.5) |
